Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Fourth-quarter and full-year 2009 results announced by Celsion

Celsion Corporation, a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and recurrent chest wall breast cancer.

17 Feb 2010

LCA announces new internet link with renowned lung cancer research center in Zhuhai, China

Lung Cancer Alliance (LCA) announced today a new internet link with a renown lung cancer research center at the 5th Affiliated Hospital of Sun Yat-Sen University, in Zhuhai, China.

15 Feb 2010

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.

12 Feb 2010

New screening system developed to discover molecules that block HCV life cycle

A newly designed system of identifying molecules for treating hepatitis C should enable scientists to discover novel and effective therapies for the dangerous and difficult-to-cure disease of the liver, says Zhilei Chen, a Texas A&M University assistant professor of chemical engineering who helped develop the screening system.

12 Feb 2010

BioSphere Medical reports fourth-quarter and full-year 2009 results

BioSphere Medical, Inc. – the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today reported financial results for the three and 12 months ended December 31, 2009.

10 Feb 2010

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

Celsion Corporation announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III ThermoDox® clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.

10 Feb 2010

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces the publication of an article, entitled “A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series," authored by Dr. Matthew C. Foote, Dr. Bryan H. Burmeister, Janine Thomas, and Dr. B. Mark Smithers, in the current issue of the peer-reviewed journal, Melanoma Research (20(1):48-51, February 2010).

10 Feb 2010

Insight into mechanism H. pylori uses to evade the immune system

Helicobacter pylori (H. pylori) is the causal agent of chronic gastritis, ulcer and gastric cancer. It has the potential to persist in the human stomach for decades, sometimes causing neither harm nor clinical symptoms. Nevertheless, on some occasions, depending on the host immune system and the strain causing the infection, the outcome can be very serious. To maintain the infection, the bacterium must adapt to survive the host defences. One way to accomplish this is to sequentially change the external proteins on the bacterial surface.

10 Feb 2010

Study provides new data about potential risk of gastric cancer in patients with intestinal metaplasia

Gastric cancer remains a significant problem globally. The relationship between intestinal metaplasia (IM) and gastric cancer has always been controversial. Generally IM is divided into subtypes on the basis of histochemical characteristics; however, this classification is confusing.

10 Feb 2010

Study explores link between HBV genotype C and liver cirrhosis

Hepatitis B virus (HBV) genotypes have distinct geographical distributions, and have been shown to differ with regard to clinical outcome and prognosis. However, the relationship between HBV genotypes and liver cirrhosis remains controversial and no study on exploring the association between HBV genotypes and subclinical cirrhosis in community-based population has been reported.

10 Feb 2010

Study shows lactobacillus is effective in improving H. pylori-infected diseases

Helicobacter pylori (H. pylori) are considered to be the most important etiological agents of chronic gastritis. The eradication of H. pyloridepends on the combination of antibiotics and acid suppression drugs.

10 Feb 2010

Data provide key information about epigenetic profiles for gastric cancer

Gastric cancer, one of the most common types of cancer, is associated with high mortality rates. In the last decades, a decrease in the worldwide incidence has been observed with some changes in the therapeutic and diagnostic options.

10 Feb 2010

IgM/IgG ratio is useful in diagnosing primary biliary cirrhosis

Previous studies have shown that assessment of immunoglobulin subclasses in plasma cells by immunohistochemistry (IHC) may be useful in the histopathologic evaluation of autoimmune liver diseases. However, further studies are necessary in order to validate the diagnostic utility of IgM and IgG immunohistochemistry in this specific scenario.

10 Feb 2010

Chi-Fu Trading to market and sell Delcath PHP Systems in Taiwan

Delcath Systems, Inc. (DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research, distribution, sales and marketing agreement for its Percutaneous Hepatic Perfusion (PHP) System (the Delcath PHP System™). The agreement grants Chi-Fu Trading Co., Ltd. the exclusive right to market and sell the Delcath PHP System in Taiwan for hepatic malignancies and infectious disease upon Taiwan Food and Drug Administration (TFDA) approval, and any other approved use, with a conditional option for Singapore.

9 Feb 2010

Study may provide new intervention strategies for esophageal adenocarcinoma

Barrett's epithelium is recognized as a complication of erosive esophagitis and is the pre-malignant condition for adenocarcinoma of the esophagus.

6 Feb 2010

Two U.S. insurers approve coverage of radioembolization for treatment of unresectable liver cancer

MDS Nordion, a global leader in providing products and services for medical imaging and radiotherapeutics, today announced that two of the largest health insurers in the United States have recently approved coverage of radioembolization to treat unresectable liver cancer, which includes the use of MDS Nordion's TheraSphere(R) treatment. The two insurance companies and their affiliates together serve more than one-quarter of Americans and do business in all 50 states.

6 Feb 2010

Study suggests environmental factors play a significant role in the etiology of Crohn's disease

Although inflammatory bowel disease (IBD) [comprising mainly Crohn's disease (CD) and ulcerative colitis (UC)] is thought to affect about 150 000 people in the United Kingdom, the prevalence of severe IBD is not known. Mortality following hospitalization for IBD is significant but little has been reported on long-term follow-up.

6 Feb 2010

Endoscopic surveillance could be an appropriate strategy for subepithelial lesions

Although several studies pertaining to the natural history of subepithelial tumors have been published, they have been limited by small sample size and relatively short follow-up. The natural history of subepithelial lesions has not been clearly elucidated, and the appropriate management strategy for small subepithelial tumors is still controversial.

6 Feb 2010

Survey finds majority of patients are interested in video recording of colonoscopy procedure

Colonoscopy is operator-dependent and substantial numbers of pre-cancerous polyps are missed during colonoscopy. Colonoscopies are often poorly documented, with only a few still photographs taken of anatomic landmarks and abnormal findings.

5 Feb 2010

Researchers evaluate ethical and legal issues of volunteers who participate in endoscopy-based studies

The involvement of healthy volunteers (HV) in clinical and preclinical research, especially in the gastroenterology, has grown dramatically over the past few years. However, many issues of ethical, methodological or even legal concerns have not been systematically studied.

5 Feb 2010

Liver Cancer News and Research

Further Reading

Fourth-quarter and full-year 2009 results announced by Celsion

LCA announces new internet link with renowned lung cancer research center in Zhuhai, China

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

New screening system developed to discover molecules that block HCV life cycle

BioSphere Medical reports fourth-quarter and full-year 2009 results

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

Insight into mechanism H. pylori uses to evade the immune system

Study provides new data about potential risk of gastric cancer in patients with intestinal metaplasia

Study explores link between HBV genotype C and liver cirrhosis

Study shows lactobacillus is effective in improving H. pylori-infected diseases

Data provide key information about epigenetic profiles for gastric cancer

IgM/IgG ratio is useful in diagnosing primary biliary cirrhosis

Chi-Fu Trading to market and sell Delcath PHP Systems in Taiwan

Study may provide new intervention strategies for esophageal adenocarcinoma

Two U.S. insurers approve coverage of radioembolization for treatment of unresectable liver cancer

Study suggests environmental factors play a significant role in the etiology of Crohn's disease

Endoscopic surveillance could be an appropriate strategy for subepithelial lesions

Survey finds majority of patients are interested in video recording of colonoscopy procedure

Researchers evaluate ethical and legal issues of volunteers who participate in endoscopy-based studies

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News